Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 13/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776244 | 0.88 | ABL1 (0.40) | ABL1MAP4K1 | |
| SCHEMBL16776177 | 0.88 | RPS6KA2 (0.40) | ABL1RPS6KA2FGFR4CYP2C9ALOX5AP | |
| SCHEMBL16776143 | 0.87 | RPS6KA2 (0.39) | ABL1RPS6KA2FGFR4CYP2C9ALOX5AP | |
| SCHEMBL16776209 | 0.86 | KCNH2 (0.42) | ABL1RPS6KA2FGFR4CYP2C9ALOX5AP | |
| SCHEMBL16776242 | 0.86 | ABL1 (0.40) | ABL1MAP4K1 | |
| SCHEMBL16776232 | 0.84 | ABL1 (0.39) | ABL1MAP4K1 | |
| SCHEMBL16776037 | 0.82 | FGFR4 (0.37) | ABL1RPS6KA2FGFR4CYP2C9ALOX5AP | |
| SCHEMBL16776247 | 0.82 | ABL1 (0.37) | ABL1MAP4K1 | |
| SCHEMBL16776028 | 0.81 | FGFR4 (0.38) | ABL1RPS6KA2FGFR4CYP2C9ALOX5AP | |
| SCHEMBL16776032 | 0.81 | KCNH2 (0.41) | ABL1RPS6KA2FGFR4CYP2C9ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ABL1 4089/4885RPS6KA2 2318/4885FGFR4 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.